Revvity has delivered four consecutive quarterly earnings beats and exceptional free cash flow conversion at 212% of net income with a perfect 9 out of 9 Piotroski score, but with only negative 1.7% upside remaining to the analyst target and 12% short interest, the stock appears fairly priced with downside risk exceeding near-term upside.
Thesis pillars
- Perfect Earnings Beat Consistency↑Improving
- Exceptional Free Cash Flow Conversion→Stable
- Weak Growth At Analyst Target↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Revvity, Inc. (RVTY) Stock Analysis
Range Bound setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $159.43, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak overall score: 4.8/10.
Revvity provides instruments, reagents, software, and services to pharmaceutical, biotech, academic, and clinical customers across two segments — Life Sciences and Diagnostics — operating in more than 160 countries with approximately 11,000 employees as of December 28, 2025.... Read more
Hold if already holding. Not a fresh buy at $159.43, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak overall score: 4.8/10. Chart setup: RSI 55 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 4.8/10, moderate confidence.
Passes 8/10 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.40, news boost analyst cluster(4), earnings proximity 88d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Revvity, Inc.
About Revvity, Inc.
Revvity's Life Sciences and Diagnostics segments collectively reach more than 160 countries with approximately 11,000 employees as of December 28, 2025, and the company is a component of the S&P 500 Index, listed on the New York Stock Exchange under RVTY. The Life Sciences segment provides reagents, instruments, and software for drug discovery, cell biology, genomics, and imaging research, including a BioLegend catalog of more than 35,000 SKUs. The Diagnostics segment provides newborn screening, prenatal testing, and infectious disease instruments and assays — covering Down syndrome, hypothyroidism, muscular dystrophy, and metabolic conditions — to diagnostic labs and public health authorities in more than 160 countries.
Revvity earns revenue through a mix of instrument sales, recurring reagent and consumable sales, software licenses, and services. The Life Sciences segment partners with pharmaceutical and biotech companies, contract research organizations, and academic institutions, offering instruments such as the Opera Phenix Plus high-content screening system and EnVision multimode plate reader alongside HTRF, LANCE Ultra, AlphaLISA, and AlphaScreen reagent technologies. Software platforms including Signals, ChemDraw, and Living Image generate recurring revenue through licensing arrangements. The Diagnostics segment's instruments and reagent kits serve hospitals, clinicians, and government agencies for early detection of conditions from pregnancy through early childhood. As of December 28, 2025, Revvity held $9.0 billion in net intangible assets, reflecting a history of technology acquisitions across both segments; potential impairment could result from adverse changes in segment business conditions or key valuation assumptions.
Show full overview
Revvity's production of certain principal products depends on limited or single-source suppliers for critical raw materials and key components that cannot always be rapidly substituted — substitution may require price increases, quality declines, or delivery delays. The company maintains multi-year supply contracts with no minimum purchase requirements with these suppliers, leaving the sourcing relationship exposed to single-supplier disruptions. Recent tariff actions on U.S. trading partners and retaliatory measures, which the 10-K identifies as potentially disruptive to Revvity's supply chain, add to this exposure. With $9.0 billion in net intangible assets at December 28, 2025 tied to acquired technology businesses, a sustained production disruption that delays or degrades product availability could impair goodwill valuations and compress margins in both segments.
See also: Healthcare · Diagnostics & Research
From Revvity, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated Nov 3, 2026Recent Developments — Revvity, Inc.
Latest news
- NEWS Revvity Inc (RVTY) Shares Fall 3.4% -- What GF Score of 70 Tells Investors - GuruFocus — GuruFocus Nov 3, 2026 negative
- NEWS Should Earnings Growth Require Action From Revvity (RVTY) Investors? - Simply Wall St — Simply Wall St Oct 27, 2026 neutral
- NEWS Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance — Yahoo Finance Oct 27, 2026 positive
- NEWS Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance — Yahoo Finance Oct 27, 2026 positive
- NEWS Revvity Inc (RVTY) Shares Fall 3.3% -- What GF Score of 75 Tells Investors - GuruFocus — GuruFocus Aug 5, 2026 negative
Latest item Nov 3, 2026 · Generated 2026-11-05T11:59:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierlimited or single source suppliers10-K Item 1A: 'certain critical raw materials, key components and other goods...are available from limited or single sources of supply'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $159.43, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Weak overall score: 4.8/10. Chart setup: RSI 55 mid-range, Bollinger mid-band. Multiple concerning factors. Consider reducing position. | News modifier +2 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Analyst target $134.88 reached (−15.4%), stop $148.27 (−7.5%), A.R:R -1.6:1. Score 4.8/10, moderate confidence.
Analyst target $134.88 reached (−15.4% from $159.43); no take-profit level is published. Analyst target $134.88 reached (−15.4%), stop $148.27 (−7.5%), A.R:R -1.6:1. Stop-loss: $148.27.
Analyst target reached - limited upside remaining; Weak overall score: 4.8/10; Weak growth.
Revvity, Inc. trades at a P/E of 70.9 (forward 26.9). TrendMatrix value score: 4.3/10. Verdict: Hold.
25 analysts rate RVTY, with a consensus score of 3.6/5. 15 analysts publish price targets averaging $150.
What does Revvity, Inc. do?Revvity provides instruments, reagents, software, and services to pharmaceutical, biotech, academic, and clinical...
Revvity provides instruments, reagents, software, and services to pharmaceutical, biotech, academic, and clinical customers across two segments — Life Sciences and Diagnostics — operating in more than 160 countries with approximately 11,000 employees as of December 28, 2025. Life Sciences products support drug discovery, cell biology, and genomics research, while the Diagnostics segment focuses on reproductive health screening, immunodiagnostics, and infectious disease testing for hospitals, medical labs, and public health authorities.